Reaction
Hyperaesthesia Teeth reporting signals
As of the last recalculation, Hyperaesthesia Teeth appears in 1,214 FAERS reports alongside 17 co-occurring drug terms. The strongest observed disproportionality signal is BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE (PRR 18.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Buprenorphine Hydrochloride, Naloxone Hydrochloride | 26 | 18.9 | 18.9 |
| Romosozumab-Aqqg | 10 | 12.7 | 12.7 |
| Budesonide | 42 | 12.6 | 12.6 |
| Abaloparatide | 20 | 11.8 | 11.8 |
| Iohexol | 5 | 10.4 | 10.4 |
| Cabozantinib | 28 | 10.2 | 10.2 |
| Ozanimod Hydrochloride | 4 | 8.3 | 8.3 |
| Calcium, Magnesium, Potassium, And Sodium Oxybates | 4 | 8.0 | 8.0 |
| Daptomycin | 4 | 7.5 | 7.5 |
| Vibegron | 3 | 6.4 | 6.4 |
| Cenegermin-Bkbj | 4 | 5.7 | 5.7 |
| Axitinib | 6 | 5.3 | 5.3 |
| Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide | 3 | 5.1 | 5.1 |
| Emtricitabine And Tenofovir Alafenamide | 3 | 4.5 | 4.5 |
| Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate | 4 | 3.8 | 3.8 |
| Relugolix | 5 | 3.6 | 3.6 |
| Dupilumab | 80 | 3.0 | 3.0 |